Introduction
Recent genetic and biochemical investigations of the molecular mechanisms governing the G 1 to S phase progression in mammalian cells demonstrated a central role for D-type cyclins and their partner cyclin-dependent kinases (CDK) 4 and 6. [1] [2] [3] [4] [5] The cell cycle-accelerating function of cyclin Dassociated kinases appears to be mediated by phosphorylation and concomitant inactivation of the retinoblastoma protein (pRb) in G 1 phase, a process negatively regulated by p16 INK4A and other CDK inhibitors. As a result, transcription factors like E2F and CBP/cycA are released, thereby inducing gene expression and metabolic changes leading to onset of DNA replication. 4, [6] [7] [8] The emerging critical role of the cyclin D1/pRb/p16 INK4A pathway in cell cycle regulation is further supported by frequent alterations of individual components of this checkpoint mechanism in human tumors. [1] [2] [3] [4] [5] 9 The chromosomal translocation t(11;14)(q13;q32), which leads to juxtaposition of the immunoglobulin heavy chain promoter and the cyclin D1 gene, resulting in overexpression of cyclin D1 is a character- istic feature of mantle cell lymphoma. 10, 11 Also, cyclin D1 amplification and overexpression is a negative prognostic factor in t(11;14)-negative lymphoproliferative disorders 12, 13 and a variety of solid tumors. 14, 15 CDK4 overexpression or mutation can be detected in various tumor types, including melanoma and glioblastoma. [16] [17] [18] Rb deletions and mutations at the chromosomal locus 13q14 are among the most common genetic aberrations found in human neoplasias. p16 INK4A deletion occurs in a broad spectrum of solid tumors and is the most frequently observed genetic alteration in adult T cell lymphoblastic leukemia. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] In addition, recently, de novo 5Ј CpG island hypermethylation has been found to be associated with transcriptional silencing of the p16
INK4A and p15
INK4B
genes in human cancer. 23 Interestingly, a reciprocal correlation between genetic alterations of single members of the pRb pathway has been described for several solid tumors. 16, 18, [24] [25] [26] An alteration of any one gene in the pathway seems to eliminate selective pressure for changes in the others, so that Rb or p16
INK4A inactivation and cyclin D1 or CDK4 overexpression are mutually exclusive events in the generation of tumor cells. In contrast, some lymphoid neoplasias do not show this alternative pattern of pRb pathway alterations. 22, 27, 28 The molecular pathogenesis of multiple myeloma (MM) is still largely unknown and, unlike other types of B cell neoplasms, no genetic lesions specifically associated with this neoplasm have yet been found. [29] [30] [31] Nevertheless, aneuploidy as detected by flow cytometric analysis of nuclear DNA content of G 0/1 cells or by fluorescence in situ hybridization (FISH) has been described in almost 90% of patients with MM. 32, 33 In contrast, due to difficulties in obtaining analyzable metaphases, abnormal karyotypes have been observed in only 30 to 45% of cases. 34, 35 Among those, only partial or complete deletions of chromosome 13 harboring the Rb gene or abnormalities involving 11q, where the cyclin D1 gene is located, are associated with poor prognosis. 35, 36 In addition, monoallelic deletions of the Rb gene locus at 13q14 have been reported to be an independent adverse prognostic variable in MM. 37 These findings suggest a potential important role of the cyclin D1/pRb/p16
INK4A pathway in the pathogenesis of MM. Therefore, we determined the frequency of Rb deletions and cyclin D1 alterations by interphase FISH as well as 5Ј CpG island hypermethylation of the p16 INK4A gene using methylation-specific polymerase chain reaction (PCR) in bone marrow mononuclear cells from three individuals with monoclonal gammopathy of undetermined significance (MGUS), 73 patients with MM, and six patients with plasma cell leukemia (PCL). To further estimate the biological effect of these alterations, the aberration state was correlated to the clinical course of the plasma cell disorders.
Patients
Heparinized bone marrow samples as well as bone marrow smears were obtained from three individuals with MGUS and 73 patients with MM. Peripheral blood samples and smears from six patients with PCL were also included. Peripheral blood samples and smears from eight normal individuals served as controls for determination of cut-off values. Bone marrow aspirations and blood drawings were performed for diagnostic purposes, and patients gave informed consent according to institutional guidelines to allowing an aliquot of the specimen to be used for research purposes. Main characteristics of patients are summarized in Table 1 .
Interphase FISH
Heparinized bone marrow or peripheral blood samples were subjected to Ficoll gradient centrifugation (density 1.077 g/ml; Pharmacia, Freiburg, Germany). Buffy coats were washed once with phosphate-buffered saline (PBS) and brought on to slides, fixed in methanol/acetic acid 3:1 and stored at −70°C. Dual-color FISH was performed as described previously. 38 Commercially available DNA probes for cyclin D1 (Vysis, Stuttgart, Germany) and the centromeric region of chromosome 11 (Vysis) as well as DNA probes for Rb/13q14.2 (digoxigenin-labeled; Oncor, Heidelberg, Germany) were used according to the manufacturer's recommendations. Cosmid contigs spanning the 14q32 IgH region and the 9p21 p16
INK4B region (8 cosmids, 250 kb) were kindly provided by Dr R Siebert (Department of Human Genetics, University of Kiel, Germany) and Dr S Bohlander (Institute of Human Genetics, University of Gö ttingen, Germany), respectively. 39, 40 From those, FISH probes were generated using a standard protocol. 41 Evaluation was performed by analyzing at least 200 interphase nuclei per sample using conventional fluorescence microscopy. For cyclin D1, two-color FISH with the unique probe and the corresponding centromeric probe 
Methylation-specific PCR
The conditions and primer sets used for methylation-specific PCR to detect methylated p16 INK4A promoter DNA are described elsewhere. 42 The PCR was performed in a final volume of 25 l containing 2.5 l buffer (10 mM Tris-HCl, 50 mM KCl, 0.1% Triton X-100), 1.5 mM MgCl 2 , 1.0 mM dNTPs, 10 pM primers, 2 units of Taq polymerase (GibcoBRL, Karlsruhe, Germany) and 60 ng of bisulfate-treated DNA. The amplification was performed in a thermal cycler (Biometra, Gö ttingen, Germany) as described. 42 A control PCR without DNA was performed for every PCR set in order to exclude contamination. Five l of each PCR product was loaded on to agarose gels (0.5% agarose and 4% Nu-Sieve), electrophoresed and visualized after ethidium bromide staining by UV illumination. If an amplification product was detected in the PCR reaction with primers specific for methylated DNA, the sample was classified as methylated. If a specific PCR product was detected exclusively after PCR with primers specific for unmethylated DNA, the sample was classified as unmethylated.
Statistical analysis
The chi square test and Fisher's exact test were used to examine the relation between any two factors. Overall survival was calculated from the date of diagnosis until the patients death or last visit. Survival probability curves were analyzed and plotted according to the method of Kaplan and Meier and compared using the log-rank test.
Results

Interphase FISH analysis of cyclin D1 and Rb
Fourteen of the 82 individuals with plasma cell disorders (17.1%) exhibited aberrations of chromosomal region 11q13, five cases (6.1%) had a translocation t(11;14)(q13;q32), and nine cases (11%) had a polysomy 11. Distribution of deletions according to the stage of the disease is shown in Table 2 . Except for one patient with stage I disease, who had a t(11;14)(q13;q32), all patients with cyclin D1 locus alterations had stage II/III MM or PCL. The percentage of cells with a t(11;14)(q13;q32) or a polysomy 11 varied between 10.9 and 72.9% and between 9.5 and 97.5%, respectively. In all diploid cases with a chromosomal translocation t(11;14)(q13;q32), two copies of the control centromeric probe for chromosome 11 were detected in 97.8 ± 2.2%, proving the reliability of the method. In the total group of 82 plasma cell disorders, cyclin D1 gene locus alterations were closely related to extramedullar or leukemic disease manifes- Table  3 ). This correlation was highly significant (P = 0.014; Fisher's test). Rb deletions were found in 23 of the 83 individuals with plasma cell disorders (28%), 20 cases (24.4%) had hemizygous deletions, and three cases (3.6%) had homozygous deletions ( Table 2 ). The percentage of cells with Rb deletions varied between 13.8 and 60.1%. Rb deletion showed no clear relation to an extramedullar or leukemic course of the plasma cell disorder (27% vs 37.5% Rb deletions in MM and EMP/PCL, respectively; P = 0.984; Fisher's test; Table 3 ).
Only three cases (3.6%) exhibited both cyclin D1 locus alterations and Rb deletions (Table 4 ). All three patients had stage III disease. Two had a t(11;14)(q13;q32) and a hemizygous Rb deletion and one had a polysomy 11 and a hemizygous Rb deletion. In the subgroup of patients with EMP or PCL, there was a highly signifcant negative correlation between cyclin D1 locus alteraltions and Rb deletions (P = 0.001, chi Table 4 Results of FISH analysis in 34 individuals with 11q13 aberrations and/or 13q14 deletions n *11q13 del(13q14) t(11;14) polysomy 11 hemizygous homozygous
square test; Table 5 ). Seven out of eight patients with EMP or PCL harbored either a cyclin D1 alteration or a Rb deletion. None of these patients had a combination of both aberrations. Both cyclin D1 locus alterations and Rb deletions were associated with a worse prognosis (P = 0.058; Figure 1a , b). Patients with and without cyclin D1 aberrations or Rb deletions had 5-year survival rates of 55% and 72%, respectively (Figure 1a) . Interestingly, no difference was found between the survival curves of patients with cyclin D1 locus alterations and Rb deletions (Figure 1b) . Five-year survival rates of both groups were identical. Of note, all three patients with concurrent cyclin D1 alterations and Rb deletions are alive at a median follow-up of 51 months. Neither cyclin D1 alterations nor Rb deletions were more frequent in patients in whom the plasma cell disorder was diagnosed 6 months or longer before FISH analysis as compared to patients with newly diagnosed disease (Ͻ6 months from initial diagnosis; Table 6 ). 
Interphase FISH analysis of p16
INK4A
FISH, fluorescence in situ hybridization; EMP, extramedullary plasmocytoma; PCL, plasma cell leukemia. (Figure 2) . Patients with and without p16 INK4A hypermethylation had identical 5 year survival rates of 72%. As with cyclin D1 alterations and Rb deletions, no statistically significant difference was found between the frequency of p16 INK4A hypermethylation in patients in whom the plasma cell disorder was
Figure 2
Survival of 57 individuals with plasma cell disorders with and without p16
INK4A 5ЈCpG island hypermethylation as detected by methylation-specific PCR. diagnosed 6 months or longer before MSP analysis as compared to patients with newly diagnosed disease (Ͻ6 months from initial diagnosis; Table 6 ).
Discussion
In the present study, an extensive analysis of the three most common mechanisms of cyclin D1/pRb/p16 INK4A pathway deregulation, namely cyclin D1 locus alteration, Rb deletion and p16
INK4A 5ЈCpG island hypermethylation revealed the abrogation of this G 1 /S phase regulatory pathway in 75% of those individuals with plasma cell disorders for whom every parameter was evaluated. Using interphase FISH and methylation-specific PCR, cyclin D1 locus aberrations, Rb deletions, and p16
INK4A 5ЈCpG island hypermethylations were identified in 17.1, 28 and 57.9% of patients with plasma cell disorders, respectively. Notably, our data indicate a correlation between cyclin D1 gene locus alteration and extramedullar or leukemic disease manifestation. In addition, at least in EMP/PCL, a reciprocal correlation between cyclin D1 alterations and Rb deletions was found whereas p16
INK4A hypermethylations occurred in addition to cyclin D1 alterations or Rb deletions. Of particular interest, cyclin D1 locus alterations and Rb deletions were associated with a worse prognosis whereas p16
INK4A hypermethylation had no impact on survival. Previous studies on cell cycle deregulation in MM are hampered by selective examination of just one component rather than multiple genes involved in G 1 /S control. 37, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] Nevertheless, those studies have already emphasized a relatively high incidence of chromosomal abnormalities involving 11q, where the cyclin D1 gene is located. Chromosomal translocation of cyclin D1 by a t(11;14)(q13;q32) has been found in 5-40% of MM patients 34, 35, 45, 46 and is closely associated with enhanced expression of cyclin D1. 55 Furthermore, it has been described that the t(11;14)(q13;q32) translocation in MM is linked to a more aggressive disease and a poorer prognosis. 35, 46 In addition to the (11;14)(q13;q32) translocation, other 11q abnormalities have also been reported to contribute to a poor prognosis in MM, with one possible mechanism being the amplification of the cyclin D1 gene as has been described for breast cancers.
14 Likewise, polysomy 11 resulting in overexpression of cyclin D1 in MM has been reported recently. 47 However, despite an association between t(11;14)(q13;q32) and an aggressive clinical course with extranodal disease and peripheral blood involvement being suggested, 35 the impact of cyclin D1 overexpression on myeloma cell circulation still remains controversial. 45, 46 In our study, cyclin D1 locus alterations including t(11;14)(q13;q32) and polysomy 11 were detected in 14/82 (17.1%) cases and closely correlated with EMP/PCL. Of note, mantle cell lymphoma frequently presents with extranodal disease including peripheral blood involvement. Moreover, cyclin D1-positive unclassified chronic lymphoproliferative disorders are characterized by a predominantly leukemic presentation and an aggressive clinical course. 13 Consistent with our observations, hemizygous deletions of chromosomal region 13q14, where the Rb gene is located, have been described at frequencies of 50% to 70% in MM by FISH analysis and are associated with a lower rate of response to chemotherapy and a shorter overall survival. [35] [36] [37] 43, 44, 56 Also in agreement with our data, in rare cases, biallelic deletions of Rb with loss of pRb expression have been reported. Deletions affecting the chromosomal region 13q14 are the most frequent genetic abnormality in chronic lymphocytic leukemia (CLL). In this disease, it has been suggested that the gene affected by the deletion at chromosomal region 13q14 is not Rb but a novel tumor suppressor gene. 57 However, the lack of a deleterious effect of such 13q deletions in CLL suggests the involvement of distinctly different genes in CLL and MM, respectively. 56 This interpretation is corroborated by recent findings of Shaughnessy and coworkers, 56 who have generated a deletion map of chromosome 13q in MM by interphase FISH with 11 probes spanning the long arm of chromosome 13. In this study a marked deletion heterogeneity with deletion evolution in different subclones of individual patients and Rb deletions in 60% of the cases have been described. In contrast to our results, Shaughnessy et al report an increased frequency of Rb deletions in patients with longstanding MM as opposed to newly diagnosed patients and therefore suggest a participation of Rb deletions in MM progression.
Interestingly, for some solid tumors, one hit at a single position of the pRb pathway seems to be sufficient to destabilize cell cycle regulation. In melanoma, there is a reciprocal correlation between pRb inactivation, p16
INK4A deletion, and CDK4 mutation. 16 Also, in glioblastoma, either Rb deletion, p16
INK4A
inactivation or CDK4 amplification have been described. 18, 24 For non-small and small cell lung cancers, reciprocal inactivations of either Rb and p16 INK4A or Rb and cyclin D1 overexpression have been described. 25, 26 These observations are in agreement with our finding of a reciprocal correlation between cyclin D1 alterations and Rb deletions in EMP/PCL. Seven out of eight patients with PCL or MM with extramedullary manifestations had strictly reciprocal alterations of the cyclin D1 or Rb locus. From 34 individuals with 11q13 aberrations or 13q14 deletions only three harbored both a cyclin D1 locus aberration and a Rb deletion. However, due to the relatively low frequencies of these alterations, no firm conclusions for the total group of patients with plasma cell disorders can be drawn. Alterations in at least one of the components of the cyclin D1/pRb/p16 INK4A pathway were found in 75% of the patients examined. Aberrations of pathway elements that have not been examined in this study may account for G 1 /S phase deregulation in additional cases. Examples like cyclin D3 overexpression by a chromosomal translocation t(6;14)(p21;q32) and p15 INK4B or p18 INK4C deletions in MM have recently been reported. 49, 58 Both cyclin D1 gene locus aberrations and Rb deletions occurred with similar incidences in newly diagnosed and longstanding plasma cell disorders, a finding that argues in favor of a role of these chromosomal abnormalities as an early event in MM development. 29 Cyclin D1 alterations as well as Rb deletions were associated with a poor prognosis. Interestingly, when analyzed separately, both types of abnormalities lead to similar survival curves, a finding that supports the view that cyclin D1 and Rb aberrations are alternative modes of G 1 /S phase deregulation with identical consequences.
In transgenic mice, the overexpression of cyclin D1 alone is not sufficient for the development of malignant lymphoma. 59, 60 Consequently, hemizygous as well as homozygous deletions of p16 INK4A have been described to occur in approximately 50% of mantle cell lymphomas in addition to its characteristic translocation t(11;14)(q13;q32) and a highly significant correlation between p16
INK4A deletions and the proliferation index has been demonstrated. 27 In addition, concomitant aberrations of p16 INK4A and cyclin D1 in several tumor cell lines of different origin, 61 concurrent overexpression of cyclin D1 and CDK4 in familial adenomatous polyposis patients, 62 and inactivation of multiple G 1 phase
